Bevacizumab in the treatment of radiation injury for children with central nervous system tumors.

ABSTRACT:

Purpose

Radiation-induced injury is a well-described toxicity in children receiving radiation therapy for tumors of the central nervous system. Standard therapy has historically consisted primarily of high-dose corticosteroids, which carry significant side effects. Preclinical models suggest that radiation necrosis may be mediated in part through vascular endothelial growth factor (VEGF) overexpression, providing the rationale for use of VEGF inhibitors in the treatment of CNS radiation necrosis. We present the first prospective experience examining the safety, feasibility, neurologic outcomes, and imaging characteristics of bevacizumab therapy for CNS radiation necrosis in children.

Methods

Seven patients between 1 and 25 years of age with neurologic deterioration and MRI f

SUBMITTER: Dahl NA 

PROVIDER: S-EPMC7251774 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature